Examkin

Soru

Zorluk: ZorPreventive Care and Screening

A 45-year-old woman comes to the ambulatory clinic for a routine wellness evaluation. She reports feeling well and has no acute symptoms. Her medical history is notable for a deep vein thrombosis in her left lower extremity 3 years ago following a 12-hour flight. She was treated with oral anticoagulation for 6 months and currently takes no medications. She has never smoked and consumes alcohol occasionally. She menstruates regularly every 28 days. Her mother was diagnosed with breast cancer at age 50 and her maternal aunt was diagnosed with the same disease at age 55. The patient is highly concerned about her own risk of developing breast cancer. She had a screening mammogram 2 weeks ago that was interpreted as BI-RADS category 1 (negative). She has read about medications that can lower breast cancer risk and requests a prescription for preventive therapy. Vital signs and physical examination are within normal limits. Which of the following is the most appropriate response regarding chemoprevention for this patient?

  1. A
    Prescribe tamoxifen
  2. B
    Prescribe raloxifene
  3. C
    Prescribe anastrozole
  4. Counsel that pharmacologic breast cancer risk reduction is contraindicatedCevap
  5. E
    Prescribe a combined oral contraceptive pill

Cevap

Counsel that pharmacologic breast cancer risk reduction is contraindicated
The correct response is to counsel the patient that pharmacologic breast cancer risk reduction is contraindicated. While this patient's strong family history places her at increased risk for breast cancer—prompting consideration for primary chemoprevention—her unique clinical profile eliminates all safe pharmacologic options. Tamoxifen is the only FDA-approved medication for breast cancer risk reduction in premenopausal women; however, as a Selective Estrogen Receptor Modulator (SERM), it carries a well-documented risk of venous thromboembolism. A prior history of deep vein thrombosis (DVT) is an absolute contraindication to its use. Other risk-reducing agents, such as raloxifene and aromatase inhibitors (e.g., anastrozole, exemestane), are strictly indicated for postmenopausal women. Therefore, with tamoxifen contraindicated by her DVT history and alternative agents contraindicated by her functioning ovaries, no pharmacologic option can be safely prescribed.

Adım Adım Çözüm

1
Assess the patient's baseline risk for breast cancer.
The patient has a strong family history (two first-degree/second-degree relatives with early-onset breast cancer), placing her at increased risk and making her a potential candidate for primary chemoprevention.
Guidelines recommend discussing risk-reducing medications for women at high risk for breast cancer.
2
Evaluate the patient's menopausal status.
Regular 28-day menstrual cycles at age 45 indicate the patient is premenopausal.
Menopausal status dictates which chemopreventive agents can be safely and effectively utilized.
3
Identify absolute contraindications in the patient's medical history.
The patient has a history of deep vein thrombosis (DVT).
A history of venous thromboembolism is an absolute contraindication to Selective Estrogen Receptor Modulators (SERMs).
4
Synthesize data to determine the appropriate pharmacologic intervention.
Tamoxifen (the only agent for premenopausal women) is contraindicated due to DVT. Aromatase inhibitors are contraindicated due to premenopausal status.
Because no approved chemopreventive agent is safe for this specific patient, pharmacologic risk reduction is contraindicated.

Anahtar Kavram

Indications and contraindications for breast cancer chemoprevention
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Preventive Care and Screening

Bu konudan daha fazla soru